Clinical trial NCT03796286: A Randomized, Crossover Study to Assess the Effects of Dietary Fiber-containing Bars on Glucose and Insulin Responses
Official title: A Randomized, Crossover Study to Assess the Effects of Dietary Fiber-containing Bars on Postprandial Glucose and Insulin Responses.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Blood Glucose
Insulin Sensitivity
Dietary Fiber
Keywords: Postprandial glucose
Meal tolerance test
Lead sponsor: Midwest Center for Metabolic and Cardiovascular Research
Sponsor class: OTHER
Collaborators: name: Ingredion Incorporated
First posted: 2019-01-08
Enrollment: 41
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Intervention model description: Randomized, controlled, three-treatment, crossover trial with one screening/baseline visit and three test visits. At each testing visit, the study product (a bar) will be consumed with water.
Primary purpose: OTHER

Brief summary: This randomized, crossover study will include four clinic visits: one screening (day -7) and three test visits (days 0, 2, 4). The objective of this study is to assess the effects of dietary fiber-containing bars, at two doses of fiber, compared to a control product, on postprandial glucose and insulin responses in healthy adult men and women.


Eligibility criteria: Inclusion Criteria:

* Male or female, 18-65 y of age, inclusive.
* Subject has a body mass index of 18.5 to 32.0 kg/m, inclusive.
* Subject is judged by the Investigator to be in generally good health on the basis of medical history and screening measurements.
* Subject is willing to consume the study products as described in the protocol.
* Subject is willing to maintain usual diet and activity patterns throughout the study.
* Subject has no plans to change smoking or other nicotine use during the study period.
* Subject is willing and able to attend all clinic visits.
* Subject has a vein access scale score of 7-10.
* Subject understands the study procedures and signs forms documenting informed consent to participate in the study and authorization for release of relevant protected health information to the study Investigator and is willing to complete study procedures.

Exclusion Criteria:

* Individual has a clinically significant gastrointestinal, endocrine (including Type 1 and Type 2 diabetes mellitus), cardiovascular, renal, hepatic, pulmonary, pancreatic, neurologic, or biliary disorder.
* Subject has pre-diabetes (fasting capillary glucose between 100 and 125 mg/dL) at screening. One re-test on a separate day will be allowed for subjects with no known history of pre-diabetes or diabetes who have a capillary glucose of 100 - 110 mg/dL at screening (visit 1).
* Individual has uncontrolled hypertension (systolic blood pressure ≥160 mm Hg or diastolic blood pressure ≥100 mm Hg) at screening.
* Individual has a history of cancer in the prior 2 years, except for non-melanoma skin cancer.
* Individual has extreme dietary habits (e.g., Atkins, vegan).
* Individual has had weight change of ±4.5 kg (10 lbs) in the previous 3 months.
* Individual has a known allergy, sensitivity, or intolerance to any ingredients in the study products.
* Individual is a female, who is pregnant, planning to be pregnant during the study period, lactating, or is of childbearing potential and is unwilling to commit to the use of a medically approved form of contraception throughout the study period.
* Individual has been exposed to any non-registered drug product within 30 days of screening.
* Individual has a condition the Investigator believes would interfere with his or her ability to provide informed consent or comply with the study protocol, or which might confound the interpretation of the study results or put the person at undue risk.

Primary outcomes:
measure: Change in the incremental area under the curve for capillary glucose.
timeFrame: Up to 120 minutes - measured at each treatment visit
Secondary outcomes:
measure: Change in the incremental area under the curve for venous glucose.
timeFrame: Up to 120 minutes - measured at each treatment visit
measure: Change in the incremental area under the curve for venous insulin.
timeFrame: Differences between the dietary fiber and control conditions following a breakfast meal tolerance test (MTT) completed at visits 2, 3, and 4 in the incremental AUC (iAUC) from pre-breakfast intake to 2 hours post breakfast intake for venous glucose.
Other outcomes:
Locations:
city: Boca Raton
country: United States
facility: MB Clinical Research
state: Florida
city: Chicago
country: United States
facility: Great Lakes Clinical Trials
state: Illinois
Study officials:
affiliation: MB Clinical Research and Consulting LLC
name: Kevin Maki, PhD
role: STUDY_DIRECTOR
References: